Study Details
Design, interventions, and primary outcomes
About This Study
This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.
Design
Interventions / Regimen
- Drug: MEN2312 — MEN2312 administered as oral tablets.
- Drug: Elacestrant — Elacestrant administered as oral tablets.
Primary Outcomes
- Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312 (Baseline through Day 28)
- Recommended Phase 2 Dose (RP2D) of MEN2312 (Baseline through Month 6)
Phase: PHASE1
Status: Recruiting
Start Date: 2024-10-25
Completion: 2029-10-23
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
- Drug: MEN2312 — MEN2312 administered as oral tablets.
- Drug: Elacestrant — Elacestrant administered as oral tablets.